Advanced search
Publication Cover
Expert Opinion on Investigational Drugs Volume 21, 2012 - Issue 5
Submit an article Journal homepage
984
Views
33
CrossRef citations to date
0
Altmetric
Reviews

Inhibition of pre-protein convertase serine kexin-9 (PCSK-9) as a treatment for hyperlipidaemia

Anthony S WierzbickiSt. Thomas' Hospital Campus, Department of Chemical Pathology, Lambeth Palace Road, London SE1 7EH, UK+0207 188 1256; +0207 188 7325; [email protected]
, DM DPhil FRCPath FAHA,
Timothy C HardmanNiche Science & Technology, London House, 243-253 Lower Mortlake Road, Richmond-Upon-Thames, London TW9 2LL, UK
, PhD &
Adie ViljoenLister Hospital, Consultant in Metabolic Medicine/Chemical Pathology, Stevenage, Hertfordshire SG1 4AB, UK
, MBBS FRCPath
Pages 667-676 | Published online: 12 Apr 2012

Citations (33)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (3)

Dania O. Govea-Alonso, Josué Beltrán-López, Jorge A. Salazar-González, Juan Vargas-Morales & Sergio Rosales-Mendoza. (2017) Progress and future opportunities in the development of vaccines against atherosclerosis. Expert Review of Vaccines 16:4, pages 337-350.
Read now
Anthony S. Wierzbicki & Adie Viljoen. (2016) Anti-sense oligonucleotide therapies for the treatment of hyperlipidaemia. Expert Opinion on Biological Therapy 16:9, pages 1125-1134.
Read now
Lorenzo Iughetti, Barbara Predieri & Patrizia Bruzzi. (2015) Novel insights on the treatment of hypercholesterolemia. Expert Review of Endocrinology & Metabolism 10:3, pages 269-271.
Read now

Articles from other publishers (30)

Forough Taheri, Eskandar Taghizadeh, Fatemeh Baniamerian, Daryoush Rostami, Ahmad Rozeian, Seyed Mohammad Gheibi hayat, Tannaz Jamialahmadi, Željko Reiner & Amirhossein Sahebkar. (2022) Cellular and Molecular Aspects of Managing Familial Hypercholesterolemia: Recent and Emerging Therapeutic Approaches. Endocrine, Metabolic & Immune Disorders - Drug Targets 22:10, pages 1018-1028.
Crossref
P. Corral & A.J. Ruiz. (2017) Inhibidores de PCSK-9, efectos sobre el cLDL e implicaciones futuras: lo que se debe saber. Hipertensión y Riesgo Vascular 34:4, pages 176-183.
Crossref
Adie Viljoen, Supriya Joshi & Anthony S. Wierzbicki. 2017. Textbook of Diabetes. Textbook of Diabetes 643 652 .
. (2016) PCSK9 Inhibition Update 2016. Journal of Cardiology & Current Research 7:1.
Crossref
Anthony S Wierzbicki & Paul Grant. (2016) Drugs for hypercholesterolaemia – from statins to pro-protein convertase subtilisin kexin 9 (PCSK9) inhibition. Clinical Medicine 16:4, pages 353-357.
Crossref
Negar Maghsoodi & Anthony S. Wierzbicki. (2016) Statin myopathy. Current Opinion in Cardiology 31:4, pages 417-425.
Crossref
Ruben Vardanyan & Victor Hruby. 2016. Synthesis of Best-Seller Drugs. Synthesis of Best-Seller Drugs 285 315 .
M. Orho-Melander. (2015) Genetics of coronary heart disease: towards causal mechanisms, novel drug targets and more personalized prevention. Journal of Internal Medicine 278:5, pages 433-446.
Crossref
Dirk J. BlomC. Stephen DjedjosMaria Laura MonsalvoIan BridgesScott M. WassermanRob ScottEli Roth. (2015) Effects of Evolocumab on Vitamin E and Steroid Hormone Levels. Circulation Research 117:8, pages 731-741.
Crossref
T. A. Walton, S. Nishtar, P. J. Lumb, M. A. Crook, M. S. Marber, J. Gill & A. S. Wierzbicki. (2015) Pro-protein convertase subtilisin/kexin 9 concentrations correlate with coronary artery disease atheroma burden in a Pakistani cohort with chronic chest pain. International Journal of Clinical Practice 69:7, pages 738-742.
Crossref
Robert Roberts. (2015) A genetic basis for coronary artery disease. Trends in Cardiovascular Medicine 25:3, pages 171-178.
Crossref
Simona Dragan, Maria-Corina Serban & Maciej Banach. (2014) Proprotein Convertase Subtilisin/Kexin 9 Inhibitors. Journal of Cardiovascular Pharmacology and Therapeutics 20:2, pages 157-168.
Crossref
Danny J. Eapen, Nima Ghasemzadeh, Naveen Bellam, Neal Bhatia, Kiran Valiani, Jia Shen, Richard J. VanDam, Peter Flueckiger, Daniel L. Molloy, Jenna Kay, Ahsan Achtchi, Bryan J. Wells, Jefferson T. Baer, Nanette K. Wenger & Laurence Sperling. 2015. PanVascular Medicine. PanVascular Medicine 1627 1664 .
Steven A. Claas, Stella Aslibekyan & Donna K. Arnett. 2015. Prevention of Cardiovascular Diseases. Prevention of Cardiovascular Diseases 117 127 .
Anthony S Wierzbicki, Dilinika Perera & Mfon Ewang-Emukowhate. (2014) Dyslipidaemia: what's around the corner?. Clinical Medicine 14:Suppl 6, pages s41-s44.
Crossref
Vishvanath Tiwari & Manoj Khokhar. (2014) Mechanism of action of anti-hypercholesterolemia drugs and their resistance. European Journal of Pharmacology 741, pages 156-170.
Crossref
Penelope Ward & Mark Bodmer. 2014. Handbook of Therapeutic Antibodies. Handbook of Therapeutic Antibodies 851 926 .
R Hajhosseiny, I Sabir, K Khavandi & A S Wierzbicki. (2014) The Ebbs and Flows in the Development of Cholesterol-Lowering Drugs: Prospects for the Future. Clinical Pharmacology & Therapeutics 96:1, pages 64-73.
Crossref
Sonny Dandona & Robert Roberts. (2014) The Role of Genetic Risk Factors in Coronary Artery Disease. Current Cardiology Reports 16:5.
Crossref
Danny J. Eapen, Nima Ghasemzadeh, Naveen Bellam, Neal Bhatia, Kiran Valiani, Jia Shen, Richard J. VanDam, Peter Flueckiger, Daniel L. Molloy, Jenna Kay, Ahsan Achtchi, Bryan J. Wells, Jefferson T. Baer, Nanette K. Wenger & Laurence Sperling. 2013. PanVascular Medicine. PanVascular Medicine 1 44 .
Wilbert S AronowAnthony S Wierzbicki. 2013. Advances in Dyslipidemia. Advances in Dyslipidemia 58 69 .
Norman Delanty & David B. Goldstein. (2013) Diagnostic Exome Sequencing: A New Paradigm in Neurology. Neuron 80:4, pages 841-843.
Crossref
Mfon Ewang-Emukowhate & Anthony S. Wierzbicki. (2013) Lipid-Lowering Agents. Journal of Cardiovascular Pharmacology and Therapeutics 18:5, pages 401-411.
Crossref
Robert Roberts. (2013) PCSK9 Inhibition—A New Thrust in the Prevention of Heart Disease: Genetics Does It Again. Canadian Journal of Cardiology 29:8, pages 899-901.
Crossref
James Barnett, Adie Viljoen & Anthony S. Wierzbicki. (2013) The Need for Combination Drug Therapies in Patients with Complex Dyslipidemia. Current Cardiology Reports 15:8.
Crossref
A. S. Wierzbicki. (2013) All at sea: new lipid-lowering drug trials continue to disappoint. International Journal of Clinical Practice 67:7, pages 595-598.
Crossref
Anthony S. Wierzbicki, Adie Viljoen, Timothy C. Hardman & Dimitri P. Mikhailidis. (2013) New therapies to reduce low-density lipoprotein cholesterol. Current Opinion in Cardiology 28:4, pages 452-457.
Crossref
Michael H. Davidson. (2013) Emerging low-density lipoprotein therapies: Targeting PCSK9 for low-density lipoprotein reduction. Journal of Clinical Lipidology 7:3, pages S11-S15.
Crossref
G. Kees Hovingh, Michael H. Davidson, John J.P. Kastelein & Anne M. O'Connor. (2013) Diagnosis and treatment of familial hypercholesterolaemia. European Heart Journal 34:13, pages 962-971.
Crossref
Maciej Banach, Dagmara Hering, Krzysztof Narkiewicz, Michal Mysliwiec, Jacek Rysz & Jolanta Malyszko. (2012) Lipids, Blood Pressure, Kidney-what was New in 2012?. International Journal of Pharmacology 8:8, pages 659-678.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.